10x Genomics, Inc. (TXG) Financials
TXG Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 922.9 million | 204.1 million |
2023-12-31 | 965.1 million | 224.1 million |
2023-09-30 | 948.5 million | 203.3 million |
2023-06-30 | 989.6 million | 196.3 million |
TXG Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -18.6 million | 36.1 million |
2023-12-31 | 22.3 million | 38.9 million |
2023-09-30 | -40.7 million | 40.2 million |
2023-06-30 | -36.9 million | 45.7 million |
TXG Net Income
No data available :(
TXG Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 371.8 million | - | 92.2 million |
2023-12-31 | 388.7 million | - | 95.4 million |
2023-09-30 | 356.9 million | - | 98.5 million |
2023-06-30 | 391.4 million | - | 99.6 million |
TXG Shares Outstanding
TXG Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 2.9 million | 68.6 million | 85.8 million | - |
2023-12-31 | 3.5 million | 55.6 million | 82.8 million | 3.3 million |
2023-09-30 | 15.4 million | 107.9 million | 82.4 million | - |
2023-06-30 | 25.4 million | 71.5 million | 91.5 million | - |
TXG Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 141.0 million | 48.1 million |
2023-12-31 | 184.0 million | 77.9 million |
2023-09-30 | 153.6 million | 58.1 million |
2023-06-30 | 146.8 million | 47.2 million |
TXG
Price: $27.48
52 week price:
Earnings Per Share: -2.18 USD
P/E Ratio: -22.71
Exchange: NMS
Sector: Healthcare
Industry: Health Information Services
Volume: 10738
Market Capitalization: 3.2 billion